Ask any Specialty Pharma leader what they want in their next executive hire and you’ll hear familiar themes: “fresh thinking,” “diverse perspectives,” “ability to challenge the status quo.” Then the search progresses, and a strong candidate gets rejected with a vague line: “They’re great, but I’m not sure they’re a culture fit.” In many organizations, that is where diverse, high‑potential leaders—especially those who don’t look, talk, or network like the current C‑suite—qui

GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving. The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.

Executive search firms live with constant peaks and troughs in demand, creating pressure on research teams, margins, and delivery quality. This article explores how flexible research capability—blending strong in‑house teams with trusted external support—can help firms manage volatile workloads, protect consultant time, and maintain consistent standards without over‑hiring or risking burnout.

What the AI Research tells us vs what people are saying! If you read recent scientific reviews on artificial intelligence (AI) in the pharmaceutical industry, you get a clear message: AI is transforming drug discovery, clinical development, manufacturing, and safety.¹⁻⁵ If you talk to bench scientists, clinical teams, or data scientists over coffee, you often hear a more complicated story: pockets of impressive success, a lot of incremental improvements, and quite a few stall